Compare WTO & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WTO | VRAX |
|---|---|---|
| Founded | 2008 | 2013 |
| Country | China | United Kingdom |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4M | 2.9M |
| IPO Year | 2021 | 2022 |
| Metric | WTO | VRAX |
|---|---|---|
| Price | $0.87 | $0.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 1.6M | ★ 15.3M |
| Earning Date | 12-26-2025 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $34,589,265.00 | $2,986.00 |
| Revenue This Year | N/A | $217,274.83 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 54.01 | N/A |
| 52 Week Low | $0.90 | $0.35 |
| 52 Week High | $440.00 | $3.20 |
| Indicator | WTO | VRAX |
|---|---|---|
| Relative Strength Index (RSI) | 50.85 | 40.58 |
| Support Level | $0.80 | $0.43 |
| Resistance Level | $1.25 | $0.50 |
| Average True Range (ATR) | 0.11 | 0.07 |
| MACD | -0.05 | -0.00 |
| Stochastic Oscillator | 13.88 | 1.67 |
UTime Ltd is engaged in the design, development, production, sales and brand operation of mobile phones, accessories and related consumer electronics. It also provides Electronics Manufacturing Services (EMS), including Original Equipment Manufacturer (OEM) and Original Design Manufacturer (ODM) services, for renowned brands. The company operates in China and its products are sold globally, including Mexico, Brazil, the United States, and other emerging markets in South Asia and Africa as well as Europe. It has two in-house brands, UTime, known as its middle-to-high end label and targets middle class consumers from emerging markets; as its low- to mid-end brand, is positioned to the grassroots consumers and price-sensitive consumers in emerging markets.
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes (HSV-1) and Human Papillomavirus (HPV).